We are live on ! Find out more
JSPR icon

Jasper Therapeutics

40 hedge funds and large institutions have $64.1M invested in Jasper Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

3% more funds holding

Funds holding: 39 → 40 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9.22% less ownership

Funds ownership: 82.62% → 73.41% (-9.2%)

48% less capital inflows, than outflows

Capital inflows: $7.47M | Capital outflows: $14.5M

Holders
40
Holders Change
+1
Holders Change %
+2.56%
% of All Funds
0.58%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
12
Reduced
7
Closed
7
Calls
$2.96M
Puts
–
Net Calls
+$2.96M
Net Calls Change
+$2.86M

JSPR Hedge Fund Activity: Q4 2023 in Review

40 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2023, worth a combined $64.1M — up 0.55% from $63.7M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new JSPR positions and 7 closed out — a net gain of 1 holder — while 12 added to existing stakes and 7 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $2.67M. The largest seller was BVF Inc, exiting entirely with an estimated $6.93M sold.

  • 40 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2023, up from 39 in Q3 2023.
  • Funds reported $64.1M of Jasper Therapeutics stock for Q4 2023, up 0.55% quarter-over-quarter.
  • 8 funds opened new Jasper Therapeutics positions in Q4 2023 and 7 closed out, a net change of +1 holder.
  • The largest Jasper Therapeutics buyer in Q4 2023 was Opaleye Management, an estimated $2.67M added.
  • The largest Jasper Therapeutics seller in Q4 2023 was BVF Inc, an estimated $6.93M sold.

Based on aggregated 13F filings for Q4 2023.